Advertisement

Tumor Biology

, Volume 33, Issue 5, pp 1639–1644 | Cite as

Nuclear p63 expression in osteoblastic tumors

  • Michael E. Kallen
  • Melinda E. Sanders
  • Adriana L. Gonzalez
  • Jennifer O. Black
  • Vicki L. Keedy
  • Kenneth R. Hande
  • Kelly C. Homlar
  • Jennifer L. Halpern
  • Ginger E. Holt
  • Herbert S. Schwartz
  • Cheryl M. Coffin
  • Justin M. M. Cates
Research Article

Abstract

Expression of the p63 tumor suppressor protein has been reported in the mononuclear stromal cells of giant cell tumor of the bone, which may represent osteoblast-precursor cells. Only a limited number of osteoblastic tumors have been studied for p63 expression thus far. We therefore examined whether p63 may serve as a marker for osteoblastic differentiation in osteosarcomas or as a differential diagnostic marker to distinguish osteoblastoma from osteosarcoma. Immunohistochemical stains for p63 were performed on a tissue microarray containing 71 chemotherapy naïve biopsy samples of osteosarcoma, 21 whole sections of osteosarcoma, and 8 osteoblastomas. Nuclear p63 was detected in seven of eight osteoblastomas but was restricted to stromal cells within primitive, immature-appearing areas of osteoid deposition. Although only 7 of 71 (10 %) biopsy samples of osteosarcoma represented on the tissue microarray were positive for p63, 7 of 21 (33 %) osteosarcomas were positive when whole tissue sections were evaluated. Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors. The relatively low prevalence of p63 expression in osteosarcoma would also seem to preclude its use as a marker of osteoblastic differentiation in skeletal sarcomas.

Keywords

p63 Osteosarcoma Osteoblastoma Tissue microarray 

Notes

Acknowledgments

The authors thank Lesley Albert for editorial assistance and Violeta Sanchez for technical assistance. This study was supported by the National Cancer Institute (Breast Cancer Specialized Program of Research Excellence (SPORE) P50CA98131) and National Institutes of Health (Vanderbilt-Ingram Cancer Center Support Grant P30CA68485).

Conflicts of interest

None

References

  1. 1.
    Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–86.PubMedGoogle Scholar
  2. 2.
    Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16:296–327.CrossRefPubMedGoogle Scholar
  3. 3.
    Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003;28:663–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development. 2006;133:1553–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2006;33:413–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol. 2004;28:1506–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee AH. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast. Histopathology. 2008;52:45–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Cates JM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ, Black CC. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol. 2008;16:251–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Dickson BC, Li SQ, Wunder JS, Ferguson PC, Eslami B, Werier JA, Turcotte RE, Kandel RA. Giant cell tumor of bone express p63. Mod Pathol. 2008;21:369–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee CH, Espinosa I, Jensen KC, Subramanian S, Zhu SX, Varma S, Montgomery KD, Nielsen TO, van de Rijn M, West RB. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol. 2008;21:531–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Wülling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 2003;34:983–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Wülling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol. 2001;127:467–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Huang L, Teng XY, Cheng YY, Lee KM, Kumta SM. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone. 2004;34:393–401.CrossRefPubMedGoogle Scholar
  15. 15.
    Park HR, Kim YW, Park JH, Maeng YH, Nojima T, Hashimoto H, Park YK. Low expression of p63 and p73 in osteosarcoma. Tumori. 2004;90:239–43.PubMedGoogle Scholar
  16. 16.
    Unni KK, Inwards CY. Dahlin's bone tumors. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 112–157.Google Scholar
  17. 17.
    Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. AFIP Atlas of tumor pathology: tumors of the bones and joints. Washington: American Registry of Pathology; 2005. p. 126–192.Google Scholar
  18. 18.
    Mirra JM, Picci P, Gold RH. Bone tumors: clinical, radiologic, and pathologic correlations. Philadelphia: Lea & Febiger; 1989. p. 143–438.Google Scholar
  19. 19.
    Dorfman HD, Czerniak B. Bone tumors. St. Louis: Mosby; 1998. p. 85–127.Google Scholar
  20. 20.
    Gonzalez AL, Cates JM. Osteosarcoma: differential diagnostic considerations. Surg Pathol Clin. 2012;5:117–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Edge SB, Fritz AG, Byrd DR, Greene FL, Trotti A, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2009. p. 281–290.Google Scholar
  22. 22.
    Cates JM, Friedman DB, Seeley EH, Dupont WD, Schwartz HS, Holt GE, Caprioli RM, Young PP. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. Int J Exp Pathol. 2010;91:335–49.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    R Development Core Team. R: a language and environment for statistical computing. Version 2.12.1. R Foundation for Statistical Computing. http://www.R-project.org
  24. 24.
    Harrell FE, Jr.. Hmisc: Harrell miscellaneous. R package version 3.8-3, 2010. http://CRAN.R-project.org/package=Hmisc
  25. 25.
    Therneau T, Lumley T. Survival: survival analysis, including penalised likelihood. R package version 2.36-2, 2010. Available at http://CRAN.R-project.org/package=survival
  26. 26.
    Brasil P. Diagnosismed. Diagnostic test accuracy evaluation for medical professionals. R package version 0.2.3, 2010. Available at http://r-forge.r-project.org/projects/diagnosismed/
  27. 27.
    Aubin JE. Mesenchymal stem cells and osteoblast differentiation. In: Bilezikian JP, Raisz LG, Martin TJ, editors. Principles of bone biology. San Diego: Academic; 2008. p. 85–108.CrossRefGoogle Scholar
  28. 28.
    Lucas DR, Unni KK, McLeod RA, O'Connor MI, Sim FH. Osteoblastoma: clinicopathologic study of 306 cases. Hum Pathol. 1994;25:117–34.CrossRefPubMedGoogle Scholar
  29. 29.
    McLeod RA, Dahlin DC, Beabout JW. The spectrum of osteoblastoma. AJR Am J Roentgenol. 1976;126:321–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Bertoni F, Bacchini P, Donati D, Martini A, Picci P, Campanacci M. Osteoblastoma-like osteosarcoma. The Rizzoli Institute experience. Mod Pathol. 1993;6:707–16.PubMedGoogle Scholar
  31. 31.
    Bertoni F, Unni KK, McLeod RA, Dahlin DC. Osteosarcoma resembling osteoblastoma. Cancer. 1985;55:416–26.CrossRefPubMedGoogle Scholar
  32. 32.
    Hosono A, Yamaguchi U, Makimoto A, Endo M, Watanabe A, Shimoda T, Kaya M, Matsumura T, Sonobe H, Kusumi T, Yamaguchi T. Hasegawa T Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma. J Clin Pathol. 2007;60:410–4.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Michael E. Kallen
    • 1
  • Melinda E. Sanders
    • 1
  • Adriana L. Gonzalez
    • 1
  • Jennifer O. Black
    • 1
  • Vicki L. Keedy
    • 2
  • Kenneth R. Hande
    • 2
  • Kelly C. Homlar
    • 3
  • Jennifer L. Halpern
    • 3
  • Ginger E. Holt
    • 3
  • Herbert S. Schwartz
    • 3
  • Cheryl M. Coffin
    • 1
  • Justin M. M. Cates
    • 1
  1. 1.Department of Pathology, Microbiology and ImmunologyVanderbilt University Medical CenterNashvilleUSA
  2. 2.Division of Hematology/Oncology, Department of MedicineVanderbilt University Medical CenterNashvilleUSA
  3. 3.Department of Orthopaedics and RehabilitationVanderbilt Orthopaedic InstituteNashvilleUSA

Personalised recommendations